High level of E-cadherin expression was demonstrated in various invasive and metastatic cancers such as prostate cancer [51], ovarian cancer [52] and glioblastoma [53], suggesting that in certain tumors E-cadherin promotes metastasis instead of suppressing tumor progression. Here, CDH1 is linked to metastatic malignant neoplasm.